Lead sponsor
Shanghai East Hospital
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
1
Active
46
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
1
Trials by status
By invitation
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes PatientsMalenot applicableBy invitation46